Author Interviews, COVID -19 Coronavirus, JAMA, Vaccine Studies / 04.11.2021

MedicalResearch.com Interview with: Rani Elwy, PhD Bridge Quality Enhancement Research Initiative Program, Center for Healthcare Organization and Implementation Research, VA Bedford Healthcare System Bedford, Massachusetts Department of Psychiatry and Human Behavior, Alpert Medical School Brown University, Providence, Rhode Island  MedicalResearch.com: What is the background for this study? Response: The VA operates a very robust, embedded quality improvement and implementation science program, of which our team is involved. As the VA was one of the first US healthcare systems to rollout COVID-19 vaccination programs, we were asked to evaluate these efforts in real-time, to provide input to VA healthcare leaders on what was going well and what could be improved. This survey reported in JAMA Network Open is one of the quality improvement efforts we engaged in. (more…)
Author Interviews, CDC, COVID -19 Coronavirus, Vaccine Studies / 02.11.2021

MedicalResearch.com Interview with: Catherine H. Bozio, PhD MPH Epidemiologist Centers for Disease Control and Prevention  MedicalResearch.com: What is the background for this study? Response: We wanted to understand what protection previous infection with SARS-CoV-2 (the virus that causes COVID-19) and COVID-19 vaccination can provide. (more…)
Author Interviews, Cancer Research, COVID -19 Coronavirus, Race/Ethnic Diversity, Radiation Therapy / 01.11.2021

MedicalResearch.com Interview with: Brianna M. Jones, MD Radiation Oncology Resident Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? Response: The COVID-19 pandemic has resulted in over 4 million deaths worldwide and, presently, there have been over 2 million cases diagnosed in New York. There have been numerous studies that demonstrate cancer patients are at increased risk of diagnosis and mortality to SARS-CoV-2 virus. Several studies have also noted socioeconomic status and race/ethnicity are associated with poorer outcomes. Within NYC, Elmhurst Hospital Center (EHC) emerged as an early epicenter in spring of 2020. The surrounding catchment area of EHC consists of a population that is 54% Latino, 33% Asian, 6% White, 4% Black, 1% Native American, and 1% other according to U.S. Census Bureau, making it one of the most racially and ethnically diverse populations in the country. Its residents are predominantly working-class immigrants with limited resources that work jobs now considered essential (e.g., delivery workers, grocery shops, et cetera). EHC continued to offer a range of cancer services throughout the pandemic. Given the high infection rate and diverse population at EHC, our study provides an opportunity to evaluate outcomes in one of the hardest hit communities to date. Therefore, our aim was to investigate patient characteristics, clinical outcomes, and predictors of COVID-19 diagnosis, severity, and mortality in patients with an active cancer diagnosis at EHC.  (more…)
Author Interviews, Cognitive Issues, COVID -19 Coronavirus, JAMA, Occupational Health / 24.10.2021

MedicalResearch.com Interview with: Jacqueline H. Becker, Ph.D. Clinical Neuropsychologist Associate Scientist Division of General Internal Medicine Icahn School of Medicine at Mount Sinai  MedicalResearch.com: What is the background for this study? What are the main findings? Response: This study leverages data being collected through the ongoing Mount Sinai Health System Post-COVID-19 Registry, which is led by Dr. Juan Wisnivesky, Professor of Medicine and Chief of the Division of General Internal Medicine at the Icahn School of Medicine at Mount Sinai and senior author of the study. Our study concluded that there may be long-term cognitive repercussions from COVID-19 that impact individuals in various age groups and across the spectrum of disease severity, although the frequency of cognitive impairment was highest among patients who were previously hospitalized for COVID-19.  (more…)
Author Interviews, COVID -19 Coronavirus, JAMA / 22.10.2021

MedicalResearch.com Interview with: Destin Groff, BA Ashley Sun BA Department of Surgery and Paddy Ssentongo MD PhD Department of Public Health Sciences Center for Neural Engineering Department of Engineering, Science and Mechanics The Pennsylvania State University, State College Penn State College of Medicine and Milton S. Hershey Medical Center Hershey, Pennsylvania  MedicalResearch.com: What is the background for this study? Response: Most people who get sick from COVID-19 will survive. However, the burden of long-term consequences among the survivors is not well-characterized. That is what inspired this study.  MedicalResearch.com: What are the main findings? Response: After compiling data from 57 studies involving 250,351 unvaccinated individuals, our study shows that more than half of those worldwide who have been diagnosed with COVID-19 experience six months after recovering. The most common sequelae involve functional mobility impairments, pulmonary abnormalities, and mental health disorders, including memory deficits, concentration difficulty, post-traumatic stress disorders, depression, and anxiety. (more…)
Author Interviews, COVID -19 Coronavirus, Statins / 22.10.2021

MedicalResearch.com Interview with: Rita Bergqvis Department of Global Public Health Karolinska Institutet Stockholm, Sweden MedicalResearch.com: What is the background for this study? Response: There is a theoretical background for the discussion regarding statins in relation to COVID. Hyperinflammation and hypercoagulability have been identified as central to the development of severe COVID and COVID related complications. Hence, drugs that modulate the host immune response and inhibit thrombosis and vascular dysfunction have received a lot of attention. Statins are known to have pleiotropic effects; apart from their cholesterol lowering properties they are thought to modulate immune system processes and decrease the risk of thrombotic events. Previous observational studies on statins and COVID had some major methodological limitations and showed varying results. (more…)
Author Interviews, COVID -19 Coronavirus, Dermatology, Respiratory / 06.10.2021

MedicalResearch.com Interview with: Lara van der Schoot  MD, PhD candidate Department of Dermatology Radboud University Medical Center Nijmegen, The Netherlands MedicalResearch.com: What is the background for this study? Response: Psoriasis is a chronic, immune mediated skin disease for which effective targeted biological agents have become available the past years. Inherent to their immunomodulatory mechanism of action, biologics might increase infections risk. We know from clinical trial data that respiratory tract infections are among the most common adverse events during biologic treatment, but real-world data is sparse. Regarding the risk of serious infections among biologic users, mostly defined as infections requiring hospitalization, previous studies provided different results and there is limited comparative data for the newer biologics available. The COVID-19 pandemic turned attention to the risk of infections among biologic users, especially for respiratory tract infections, as they might relate to susceptibility for viral respiratory tract infections such as COVID-19. In our study, the primary aim was to determine the risk of respiratory tract infections among real-world psoriasis patients treated with biologics, including the newer IL-17 and IL-23 inhibitors. The secondary aim was to assess risk of serious infections in this cohort. Additionally, rates of SARS-CoV-2 infections were assessed. (more…)
Author Interviews, CDC, COVID -19 Coronavirus, Vaccine Studies / 30.09.2021

MedicalResearch.com Interview with: Anne Hause PhD Epidemiologist Centers for Disease Control and Prevention  MedicalResearch.com: What is the background for this study? Response: On August 12, 2021, the Food and Drug Administration (FDA) amended Emergency Use Authorizations (EUA) for the Pfizer-BioNTech and Moderna COVID-19 vaccines to authorize administration of an additional dose following completion of a primary vaccination series to eligible persons with moderate to severe immunocompromise.  (more…)
Author Interviews, COVID -19 Coronavirus, Pediatrics, Vaccine Studies / 28.09.2021

MedicalResearch.com Interview with: Jonathan Baktari, MD CEO of e7health.com Dr. Baktari, CEO discusses Pfizer’s recent announcement that their vaccine trial for children ages 5-11 has been safe and effective, marking a major milestone in the fight against COVID-19.   MedicalResearch.com: What risks should parents weigh? Response: Pfizer has already said that based on their studies the lower dose two shot COVID vaccine for children is safe, meaning that their data shows minimal side effects. If that data is correct, then we should expect the same minor symptoms we see with teenagers to the COVID vaccine  (more…)
Author Interviews, CMAJ, COVID -19 Coronavirus, Pediatrics / 27.09.2021

MedicalResearch.com Interview with: Shaun K. Morris MD, MPH, FRCPC, FAAP, DTM&H Divisions of General Pediatrics Clinician-Scientist, Division of Infectious Diseases Division of Infectious Diseases at the Hospital for Sick Children (SickKids) for the Canadian Paediatric Surveillance Program COVID-19 Study Team MedicalResearch.com: What is the background for this study? Response: The SARS-CoV-2 virus can cause the disease we now call COVID-19. In early 2020, when the SARS-CoV-2 virus first spread outside of China, it quickly became apparent that cases may be seen in Canada. It was not known at the time how infection with the virus would affect children and youth. Because more severe disease from other respiratory viruses often disproportionally affect the very young, we expected that a similar pattern may be seen with SARS-CoV-2. We also did not know if children and youth with certain underlying medical conditions may be at higher risk for more severe disease. Ultimately, this study was designed to get a better understanding of how often children and youth in Canada are hospitalized with SARS-CoV-2 infection, how often severe disease happens, and which children or youth may be at higher risk for severe disease.      (more…)
Author Interviews, CDC, COVID -19 Coronavirus, Vaccine Studies / 17.09.2021

MedicalResearch.com Interview with: Scott Pauley Press Officer, News Media Branch Division of Public Affairs Office of the Associate Director for Communication MedicalResearch.com: What is the background for this study?
  • In this real-world study of vaccine effectiveness:
    • Researchers compared hospitalized patients who tested positive for the virus that causes COVID-19 (case patients) to hospitalized patients who tested negative for the virus (control patients)
    • Vaccine effectiveness was calculated for each type of vaccine by comparing the proportion of cases patients and control patients vaccinated
    • 3,689 patients were included (1,682 case-patients and 2,007 control-patients)
Vaccination status breakdown: 2,362 unvaccinated; 476 fully vaccinated with Moderna; 738 fully vaccinated with Pfizer-BioNTech; and 113 fully vaccinated with Janssen vaccine. (more…)
Author Interviews, COVID -19 Coronavirus, JAMA, Vaccine Studies / 03.09.2021

MedicalResearch.com Interview with: Jeffrey M. Wilson MD Assistant Professor of Medicine Allergy and Immunology University of Virginia MedicalResearch.com: What is the background for this study? What are the main findings? Response: To date there have been few head-to-head studies evaluating the immune responses to COVID-19 vaccines. Here we measured IgG antibodies to the SARS-CoV-2 spike-RBD in adults who received full vaccination with either the Pfizer/BioNTech or Moderna vaccine. Our study is distinguished from many others because we developed a quantitative test with a read-out in standardized units (expressed as micrograms/mL). We found that antibody levels to the SARS-CoV-2 spike receptor-binding domain were lower in recipients of the Pfizer/BioNTech than Moderna vaccine. The difference in the antibody levels between vaccines was most evident in relatively older subjects. (more…)
Author Interviews, COVID -19 Coronavirus, Vaccine Studies / 02.09.2021

MedicalResearch.com Interview with: David H. Canaday, MD Associate Director of Research Geriatric Research, Education and Clinical Center (GRECC),  Cleveland VA Professor, Division of Infectious Disease, Case Western Reserve University Cleveland, Ohio MedicalResearch.com: What is the background for this study? Response: We were interested in following up on a prior study where we determined that nursing home residents, and in particular those that were given the Pfizer shot who never had COVID-19 in the past, had 4 fold less antibodies against the key Spike protein of the coronavirus than did the group of health care workers who were the other group studied. We wanted to see how those antibodies levels in these groups held up over 6 months.  (more…)
Author Interviews, Biomarkers, COVID -19 Coronavirus, JAMA / 28.08.2021

MedicalResearch.com Interview with: Laura Holberger, PhD Vice President, Strategic Partnerships Biolabs MedicalResearch.com: What is the background for this study? Response: Dr. Laura Holberger is the lead author of a JNO article published today describing the results of a research study done on behalf of BioLabs, a global network of coworking laboratory spaces, and the Cambridge Consortium for Rapid COVID Tests (CCRCT). BioLabs co-sponsored the study which helped validate a high-frequency testing protocol using an antigen test for COVID-19 under development by E25Bio Inc., a biotechnology company that develops rapid tests for infectious diseases.  The study involved twice-weekly testing of members and affiliates working in person at coworking laboratories in Cambridge and Boston, Massachusetts from September 2020 through March 2021. (more…)
Author Interviews, COVID -19 Coronavirus, Critical Care - Intensive Care - ICUs, Lancet, Pulmonary Disease / 26.08.2021

MedicalResearch.com Interview with: Jie Li, PhD, RRT, RRT-ACCS, RRT-NPS, FAARC Department of Cardiopulmonary Sciences Division of Respiratory Care Rush University, Chicago MedicalResearch.com: What is the background for this study? Response: Prone positioning has been shown to improve oxygenation and reduce mortality in intubated patients with acute respiratory distress syndrome (ARDS), as placing patients on their stomachs can help open alveoli and reduce ventilation to perfusion mismatch. At early pandemic, clinicians tried prone positioning for non-intubated patients with COVID-19 and found improvement in oxygenation. However, the evidence for patient outcomes such as intubation or mortality is still lacking. Thus we organized this international, multicenter, randomized controlled meta-trial, with 41 hospitals in 6 countries participated. (more…)
COVID -19 Coronavirus, PLoS / 07.08.2021

MedicalResearch.com Interview with: Melanie Bell, PhD, MS Professor Mel and Enid Zuckerman College of Public Health The University of Arizona MedicalResearch.com: What is the background for this study? Response: In May 2020 my colleagues began a cohort study called CoVHORT, which  aimed to investigate the impacts of the SARS-Cov-2 pandemic among residents of Arizona. The current study on long covid is a sub-study which included all CoVHORT participants who had a confirmed positive COVID-19 test, were not hospitalized, and had symptom data 30 days are longer since the test. We wanted to investigate the prevalence of long covid, also known as post-acute sequalae of COVID-19 (PASC) amongst people who did not experience severe acute infection. Although the definition is still evolving in the research community, we defined PASC as continuing to experience at least one symptom 30 days or longer post-acute infection. (more…)
Author Interviews, COVID -19 Coronavirus, Occupational Health, Weight Research / 01.08.2021

MedicalResearch.com Interview with: https://www.newtopia.com/Jeff Ruby, JD, MBA, Founder and Chief Executive Officer Leonard Fensterheim, MPH Vice President of Analytics MedicalResearch.com: What is the background for this study? What are common weight-change findings during the pandemic?  Obesity has been linked to increased risk of serious complications and the need for costly medical utilization – all of which has been exacerbated by the COVID-19 pandemic. There has been an increase of imposed restrictions that impact healthy lifestyles – the closing of gyms as an example – leading to additional stress and the complete disruption of daily lives. It’s no surprise that many people have gained weight since the beginning of the pandemic. According to the Centers for Disease Control and Prevention (CDC), before the pandemic, about 40% of Americans had obesity in the United States. This was already an alarming figure, but given that the American Psychological Association found that 42% of U.S. adults report undesired weight gain, with an average gain of 29 lbs. since the start of the pandemic, we expect that percentage has continued to grow. Against this backdrop, Newtopia sought to evaluate the impact of a guided habit change program on weight loss for 12 months during the COVID-19 pandemic. Method:
  • This was a retrospective study that looked at 1436 participants who began participating in the Newtopia experience in early 2020.
  • This analysis focused on weight change and was restricted to those participants with a body mass index >
  • 52% of participants were female, and the average age of the total study population was 46.5 years old (±10.6).
  • The percentage of participants with a 4.3% weight reduction after 12 months was assessed. This has been shown to be associated with meaningful reduction in healthcare costs.
  • The average weight loss and the percentage BMI decrease was also assessed.
  Outcomes:
  • 77% of participants lost weight.
  • 44% of participants had a weight loss of >3%.
  • Average weight loss was 4.2% (p<.0001).
  • 22% of obese participants dropped a BMI category.
Despite the challenges of the Covid-19 pandemic, individuals participating in the Newtopia habit change experience still achieved impactful weight loss. (more…)
Author Interviews, Cognitive Issues, COVID -19 Coronavirus, Imperial College, Lancet / 28.07.2021

MedicalResearch.com Interview with: Dr. Adam Hampshire PhD Faculty of Medicine Department of Brain Sciences Imperial College London MedicalResearch.com: What is the background for this study? Response: During 2020 I was leading a study that sought to map the distribution of cognitive abilities and aspects of mental health across the UK population. The study generated a lot of interest because it was a collaboration with BBC2 Horizon, leading to ~390,000 participants. When the pandemic began to escalate in the UK a number of my colleagues at Imperial and elsewhere contacted me to note that the study could be used to investigate the impact of both the pandemic and direct illness on daily life, mental health and cognition. I had been thinking along similar lines so decided to add questionnaires about peoples' experiences with the pandemic and Covid-19 illness. (more…)
Allergies, Author Interviews, COVID -19 Coronavirus, JAMA, Vaccine Studies, Vanderbilt / 27.07.2021

MedicalResearch.com Interview with: Kimberly G. Blumenthal, MD, MSc Massachusetts General Hospital The Mongan Institute Boston, MA 02114 Matthew S. Krantz, MD Division of Allergy, Pulmonary and Critical Care Medicine Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee   MedicalResearch.com: What is the background for this study? Response: During the initial COVID-19 vaccine campaign with healthcare workers in December 2020, there was an unexpected higher than anticipated rate of immediate allergic reactions after Pfizer and Moderna mRNA vaccines.  This prompted both patient and provider concerns, particularly in those with underlying allergic histories, on the associated risks for immediate allergic reactions with the mRNA vaccines. Because of the significantly improved effectiveness of two doses of an mRNA vaccine compared to one dose, it was important to determine if those who experienced immediate allergic reaction symptoms after their first dose could go on to tolerate a second dose safely.    (more…)
Author Interviews, Cancer Research, COVID -19 Coronavirus, JAMA, Prostate Cancer, Race/Ethnic Diversity / 23.07.2021

MedicalResearch.com Interview with: Andres F. Correa, MD Assistant Professor Department of Surgical Oncology, and Adrien Bernstein, MD Second Year Urologic Oncology Fellow Fox Chase Cancer Center MedicalResearch.com: What is the background for this study? Response: Unfortunately, it has been well-established that historically Black Americans experience increased cancer specific mortality compared to white patients. In prostate cancer specifically studies have shown that when access to care is equitable this gap resolves. This suggests that biological factors are not driving these differences but rather the result of the complex interplay of social determinants and systemic inequities in our healthcare system. Early in the pandemic, multiple studies demonstrated that minority communities disproportionately shouldered poor COVID-19 outcomes.  On March 13th 2020, the American College of Surgeons recommended against elective procedures; however, the definition of an elective oncologic case was left to the discretion of the provider. As prostate cancer treatment can be safely deferred up to a year follow diagnosis, management of prostate cancer during the initial lockdown period of the COVID-19 Pandemic provided a useful analysis of the differential restrictions placed on non-emergent health care during the Pandemic. (more…)
Author Interviews, COVID -19 Coronavirus, JAMA / 15.07.2021

MedicalResearch.com Interview with: Michael Ohl, MD, MSPH Associate Professor of Internal Medicine-Infectious Diseases Roy J. and Lucille A. Carver College of Medicine University of Iowa MedicalResearch.com: What is the background for this study? Response: The background is that remdesivir was approved for treatment in 2020 largely based on the results of the Adaptive COVID-19 Treatment Trial 1 (ACTT-1), which found that remdesivir treatment was associated with more rapid recovery from illness among people hospitalized with COVID-19. The intention was that - even if remdesivir did not lead to substantial improvements in survival-  it could help people to recover more quickly and be discharged from hospital sooner, potentially opening scare hospital pends to treat more patients during the pandemic.   (more…)
Author Interviews, CDC, COVID -19 Coronavirus, Heart Disease, JAMA, UCSD / 01.07.2021

MedicalResearch.com Interview with: Margaret Ryan MD MPH Medical Director of Defense Health Agency Immunization Healthcare Division Pacific Region Office, San Diego CA Clinical Professor at the University of California San Diego MedicalResearch.com: What is the background for this study? What are the main findings? Response: Military clinicians, especially those in the Defense Health Agency Immunization Healthcare Division, first became aware of a few cases of myocarditis following COVID-19 vaccination in early Feb 2021.  These cases included young men who presented with chest pain a few days after 2nd dose of mRNA (Pfizer or Moderna) vaccine.  As more young people became eligible for 2nd doses of vaccine, more cases were identified.  By late April, the military had identified 23 cases of myocarditis, with remarkably similar presentations, after COVID-19 vaccination.  This case series is described in the current issue of JAMA Cardiology. (more…)
Author Interviews, COVID -19 Coronavirus, Environmental Risks / 30.06.2021

MedicalResearch.com Interview with: Els M. Broens DVM, PhD, Dipl. ECVM, EBVS European Veteirnary Specialist in Veterinary Microbiology Associate Professor / Director VMDC Department Biomolecular Health Sciences (Clinical Infectiology) Faculty of Veterinary Medicine | Utrecht University MedicalResearch.com: What is the background for this study? Response: Several events have demonstrated that SARS-CoV-2 can infect animals, felines and mustelids in particular. In companion animals these are currently considered to be incidents with a negligible risk for public health since the main force of the pandemic is transmission between humans. However, it is urgent to understand the potential risk of animal infections for public health in the later stages of the pandemic when SARS-CoV-2 transmission between humans is greatly reduced and a virus reservoir in animals could become more important. Incidental cases have shown that COVID-19 positive owners can transmit SARS-CoV-2 to their dog or cat. The close contact between owners and their dogs and cats and the interaction between dogs and cats from different households raises questions about the risk for pets to contract the disease and also about role of these animals in the transmission of SARS-CoV-2. (more…)
Author Interviews, COVID -19 Coronavirus, Vaccine Studies / 22.06.2021

MedicalResearch.com Interview with: Dr Boby Varkey Maramattom MD,DM, FRCP, FRCPE Fellow in Critical care neurology (Mayo Clinic) Lead Consultant Neurologist Aster Medcity, Kochi, Kerala Associate Director- Clinical Research Centre, Aster Medcity. Convener, Neurocritical care subsection Indian academy of Neurology  (IAN) MedicalResearch.com: What is the background for this study? Response:  Approximately 2-3 months after the vaccination programme commenced in India, we began to notice an uptick in the incidence of Guillain-Barré Syndrome (GBS) in our community. All the cases that presented to us during this period had almost the same clinical presentation. They presented within a few days ( usually within 1-2 weeks) of the first dose of the ChAdOx1-S/nCoV-19 vaccine. Most of the patients were women and it seemed to involve the middle aged to elderly age groups. As a result of this observation, we started to compile the clinical findings of these patients and collate them. (more…)
COVID -19 Coronavirus / 15.06.2021

MedicalResearch.com Interview with: Jonathan Baktari, MD CEO of e7health.com Dr. Baktari, CEO discusses the COVID-19 Delta COVID-19 variant and his insights into pandemic concerns and control. MedicalResearch.com: What is meant by the 'Delta' variant?  Are there differences in the clinical presentation or complications?  Response: Variants are now given Greek lettering for everyone and the Delta variant represents the variant from India. Pulmonary reports indicate it is much more contagious and there are reports of increased hospitalization with this variant.  MedicalResearch.com: Where is the variant currently found and where is it likely to spread? Response: Obviously India, but it has taken over as the dominant strain in England and it is about 6% of the strains in the United states and growing. (more…)
Author Interviews, CDC, COVID -19 Coronavirus, JAMA, Pediatrics / 11.06.2021

MedicalResearch.com Interview with: Angela P. Campbell, MD, MPH Medical Officer Epidemiology and Prevention Branch in the Influenza Division MIS-C Incidence Authorship Group CDC MedicalResearch.com: What is the background for this study?
  • Response: Multisystem inflammatory syndrome in children (MIS-C) is a serious condition associated with COVID-19 where different body parts can become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, and gastrointestinal organs. Children with MIS-C may have a fever and various symptoms, including abdominal (gut) pain, vomiting, diarrhea, neck pain, rash, bloodshot eyes, or feeling extra tired. Not all children with MIS-C have the same symptoms.
  • It is still not known exactly how MIS-C may be linked to prior COVID-19 infection. However, 99% of cases in the CDC national surveillance system tested positive for COVID-19. The remaining 1% were around someone with COVID-19.
  • MIS-C incidence might vary by certain patient characteristics, such as such as race, ethnicity, age, sex and geographic location.
  • In this study we estimated the rate of MIS-C cases overall in the general population as well as the rate of MIS-C cases among those with COVID-19.
(more…)
Author Interviews, COVID -19 Coronavirus, Johns Hopkins, Nutrition / 04.06.2021

MedicalResearch.com Interview with: Dr. Hyunju Kim Ph.D. Johns Hopkins School of Public Health MedicalResearch.com: What is the background for this study? Response: In the past few months, we have learnt that individuals with comorbidities (obesity, type 2 diabetes, cardiovascular disease, hypertension) are at higher risk of Covid-19. The etiology of these conditions is largely driven by poor nutrition and unfavorable lifestyle choices, yet no study examined whether dietary habits play a role in Covid-19 infection, severity of symptoms, and duration of illness. (more…)
Author Interviews, COVID -19 Coronavirus, Sleep Disorders, Technology / 03.06.2021

MedicalResearch.com Interview with: Michele Ferrara, PhD. Professor of Psychobiology and Physiological Psychology Chair of the Psychology Didactic Council Department of Biotechnological and Applied Clinical Sciences University of L'Aquila MedicalResearch.com: What is the background for this study? Response: During the current period of social distancing, the pervasive increase in the use of electronic devices (smartphones, computers, tablets and televisions) is an indisputable fact. Especially during the long lockdown period of Spring 2020, technologies played a pivotal role in coping with the unprecedented and stressful isolation phase. However, exposure to backlit screens in the hours before falling asleep can have serious repercussions on sleep health: on the one hand, by mimicking the effects of exposure to sunlight, and thus interfering with the circadian rhythm of the hormone melatonin, and on the other hand, counteracting the evening sleepiness due to the emotionally and psycho-physiologically activating contents. In light of this assumption, we decided to test longitudinally during the third and the seventh week of lockdown a large Italian sample (2123 subjects) through a web-based survey. We assessed sleep disturbances/habits and the occurring changes of electronic device usage in the 2 hours before the sleep onset. (more…)
Author Interviews, COVID -19 Coronavirus, Vaccine Studies / 23.05.2021

MedicalResearch.com Interview with: Jonathan Baktari, MD CEO of e7health.com Dr. Baktari dicusses COVID-19 vaccinations as well as the nine vaccinated New York Yankees have now tested positive for COVID-19.  They all received the J&J vaccine. MedicalResearch.com:  There are nine known COVID positive results among members of the Yankees, previously immunized with the J&J vaccine.  Do you know if the players have become ill or just tested positive on routine testing? Response: Only 1 out of the 9 was mildly symptomatic and were all picked up as part of MLB testing protocol. MedicalResearch.com: Do you know how long after they were vaccinated that they tested positive?  Do you know of other incidences of positive reactions after vaccinations?  Response: According to MLB, all players tested positive after receiving the J&J vaccine.  All were at least 14 days after the vaccine was administered.  The 14 days post vaccination is when J&J is supposed to be effective in preventing serious illness and death. (more…)
Author Interviews, COVID -19 Coronavirus, Heart Disease, JACC, Social Issues / 12.05.2021

MedicalResearch.com Interview with: Kobina Hagan MBBS, MPH Postdoctoral Fellow Center for Outcomes Research, Houston Methodist Research Institute MedicalResearch.com: What is the background for this study? Response: Before the COVID-19 vaccination roll-out, risk mitigation guidelines including respiratory hygiene, social distancing, and job flexibility, were the most effective preventive measures against coronavirus transmission. Social determinants of health scholarships had identified social circumstances to limit adherence to these mitigation guidelines. Individuals with underlying cardiovascular disease are identified as high-risk phenotypes for severe COVID-19 outcomes. In addition, research efforts during the early and middle waves of the pandemic had identified coronavirus exposure risk as a greater mediator of the observed COVID-19 disparities, compared to clinical susceptibility from comorbidities. Yet, population-based evidence on the practice of these mitigation guidelines in this high-risk group were lacking. Consequently, we believed there was a need to robustly characterize COVID-19 risk mitigation practices among adults with cardiovascular disease in the nation. The COVID-19 Household Impact Survey was a survey conducted by the National Opinion Research Center at the University of Chicago, to provide statistics about health, economic security, and social dynamics of the US adult household population nationwide and for 18 geographic areas (10 states, 8 metropolitan statistical areas) between April and June 2020. This survey complemented the Household Pulse Survey by the Census Bureau. In this study we described the COVID-19 risk mitigation practices among patients with CVD and evaluated the association between cumulative social determinants of health burden (a measure of social adversity) and adherence these measures.  (more…)